Enliven Therapeuticsincis A Clinical Stage Biopharmaceutical Company Based In Bouldercoloradofounded In 2016The Company Specializes In The Discovery And Development Of Small Molecule Therapeuticsparticularly Kinase Inhibitorsto Enhance Patient Outcomes In Oncologyenliven Therapeutics Went Public On March 122020 The Company Is Focused On Developing Innovative Treatments For Cancerwith A Mission To Help Patients Not Only Live Longer But Also Improve Their Quality Of Lifetheir Product Pipeline Includes Elvn 001A Bcr Abl Kinase Inhibitor In Phase 1 Trials For Chronic Myeloid Leukemiaand Elvn 002A Cns Penetrant Her2 Inhibitor In Phase 1 Trials For Non Small Cell Lung Cancer And Other Her2 Driven Cancersenliven Therapeutics Aims To Address Unmet Needs In Precision Oncology Through These Promising Therapies
